ABEO

2.4201.22%
KA

Keith Alan Goldan

Executive Officer

Mr. Keith Alan Goldan, CPA, is Independent Director of Abeona Therapeutics Inc. from April 1, 2026. Mr. Goldan served as Chief Financial Officer at Syndax Pharmaceuticals, Inc. since June 13, 2022 until November 9, 2026, was its Treasurer until November 9, 2026 and was its Principal Accounting Officer since May 5, 2023 until November 9, 2026 and remains with the Company through the end of 2026. Mr. Goldan served as the Chief Financial Officer of OptiNose US Inc., Optinose, Inc. and OptiNose AS since January 26, 2017. Mr. Goldan is responsible for the financial leadership of the company, including investor relations. Prior to joining OptiNose, he served as the Chief Financial Officer, Senior Vice President and Treasurer at Fibrocell Science, Inc. from March 18, 2015 to January 25, 2017 and also served as its Corporate Secretary from March 18, 2015 to June 2015. From March 2014 to March 2015, he served as a financial and operational consultant to companies in the pharmaceutical industry. He served as the Chief Financial Officer and Senior Vice President of NuPathe, Inc. (acquired by Teva Pharmaceutical Industries Ltd.) from November 10, 2008 to March 2014 and served as its Principal Accounting Officer. He served as Vice President of NuPathe, Inc. since November 10, 2008. He served as the Chief Financial Officer at PuriCore Plc (formerly Sterilox Technologies Inc and Realm Therapeutics Plc) from October 2004 to November 1, 2008 and its Executive Director from April 21, 2006 to November 1, 2008. He has been a Member of the board of directors at OptiNose US, Incorporated since March 2021. He served as the Chief Financial Officer, Secretary, Treasurer and Vice President of Biosyn, Inc. Mr. Goldan served as Director of Strategic Analysis for ViroPharma Incorporated. He also spent four years with Healthcare & Life Sciences Practice of KPMG, served in the Health Ventures group, where he participated in all stages of transaction execution including market research, document drafting, solicitation of deal partners and deal term negotiations. He has years of executive finance and operational leadership experience in biopharmaceutical and medical technology companies. He was a Co-Founder and Associate Director of Century Capital Associates, where he was actively involved in proposing, structuring and finishing financial transactions including raising capital, strategic partnering and mergers and acquisitions in the health care industry. Mr. Goldan has a B.S. in Finance from the Robert H. Smith School of Business at the University of Maryland and an MBA from The Wharton School at the University of Pennsylvania.

公司职务